Scarica l'app Stockscreener
3.74
4.18%
0.15
Dopo l'orario di chiusura:
3.73
-0.01
-0.27%
Precedente Chiudi:
$3.59
Aprire:
$3.52
Volume 24 ore:
197.03K
Relative Volume:
0.32
Capitalizzazione di mercato:
$47.72M
Reddito:
-
Utile/perdita netta:
$-17.12M
Rapporto P/E:
-2.3823
EPS:
-1.5699
Flusso di cassa netto:
$-15.68M
1 W Prestazione:
+6.86%
1M Prestazione:
+76.42%
6M Prestazione:
+6.55%
1 anno Prestazione:
+22.62%
Intervallo 1D:
$3.41
$3.78
Intervallo di 1 settimana:
$3.16
$3.78
Portata 52W:
$1.11
$5.7441
Lantern Pharma Inc Stock (LTRN) Company Profile
Nome
Lantern Pharma Inc
Settore
Industria
Telefono
972-277-1136
Indirizzo
1920 MCKINNEY AVENUE, DALLAS, TX
Compare LTRN vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
3.74 | 45.80M | 0 | -17.12M | -15.68M | -1.5699 |
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.59B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
600.66 | 64.45B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
836.09 | 51.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.63 | 40.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
163.68 | 33.48B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-10-07 | Iniziato | H.C. Wainwright | Buy |
Lantern Pharma Inc Borsa (LTRN) Ultime notizie
LTRN News | LANTERN PHARMA INC (NASDAQ:LTRN) - ChartMill
LTRN Technical Analysis | Trend, Signals & Chart Patterns | LANTERN PHARMA INC (NASDAQ:LTRN) - ChartMill
Lantern Pharma (LTRN) Q1 2025 Earnings Transcript - AOL.com
Lantern Pharma receives FDA clearance for trial amendments - Investing.com UK
Lantern Pharma receives FDA clearance for trial amendments By Investing.com - Investing.com South Africa
Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC - BioSpace
Lantern Pharma (LTRN) Receives FDA Support for Phase 2 Trial - GuruFocus
Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC - TradingView
About Us - FinancialContent
Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates - BioSpace
Lantern Pharma (LTRN) Q1 2026: EPS -$0.30 Beats Est. -$0.36; Rev - GuruFocus
Lantern Pharma Inc (LTRN) Stock Price, Quote, News & History - Benzinga
LANTERN PHARMA ($LTRN) Releases Q1 2026 Earnings - Quiver Quantitative
Lantern Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Bios funds report 4.48% Lantern Pharma (NASDAQ: LTRN) stake - Stock Titan
Lantern Pharma (NASDAQ: LTRN) cuts R&D, advances oncology pipeline and AI spin-out - Stock Titan
Lantern Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Lantern Pharma (NASDAQ: LTRN) raises $4.4M and plans withZeta.ai spinout - Stock Titan
Lantern Pharma Sees Funding Sufficient Until Mid-1Q27 >LTRN - Moomoo
Lantern Pharma Releases Q1 2025 Financial Results - AlphaStreet
Lantern Pharma Announces $9.25 Million Registered Direct Offering and Plans for Independent AI Entity with withZeta.ai 1 - Minichart
Why is Lantern Pharma stock soaring Monday? - MSN
Insider Buying: Lee Schalop Acquires 48,544 Shares of Lantern Ph - GuruFocus
Lantern Pharma raises capital, plans AI platform spinoff - TipRanks
Lantern Pharma Raises $4.4 Million in Registered Direct, Adds Private Warrants; Engages Rodman and Renshaw - TradingView
Lantern Pharma (NASDAQ: LTRN) closes $4.4M offering and outlines AI spin-out - Stock Titan
Lantern Pharma closes $4.4M registered direct offering - Investing.com
Lantern Pharma closes $4.4M registered direct offering By Investing.com - Investing.com Australia
Lantern Pharma (LTRN) director buys shares and long-dated warrants - Stock Titan
Lantern Pharma (LTRN) director adds shares and long-dated stock warrants - Stock Titan
Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor - Yahoo Finance
Lantern Pharma (NASDAQ: LTRN) sells 1.45M shares, pre-funded warrants included - Stock Titan
Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor - BioSpace
Lantern Pharma Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Lantern Pharma raises $4.4M in registered direct offering - Investing.com UK
Lantern Pharma Inc. announces up to $9.25 million registered direct offering with existing holders and a single institutional investor - marketscreener.com
Lantern Pharma raises $4.4M in registered direct offering By Investing.com - Investing.com Australia
Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026 - BioSpace
Lantern Pharma (LTRN.US) will release its earnings report after the market closes on May 15. - Moomoo
Press Release: Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026 - Moomoo
What Lantern Pharma (LTRN) is doing to protect its market share (Trend Weakens) 2026-05-08Wall Street Picks - newser.com
Top pre-market gainers today — ELAB, ITRM, LTRN among stocks soaring before the bell - MSN
Lantern Pharma Inc. Unveils Roadmap for Withzeta.Ai with Launch of Zetaswarm and Zetaomics - marketscreener.com
Lantern Pharma Unveils Roadmap for withZeta.ai — Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm™ and ZetaOmics™ - Business Wire
Lantern Pharma Inc Azioni (LTRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.00%
3.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):